Home > Result Summaries: Compounds > naratriptan > Result Summary for S2WB1003

Result Summary for S2WB1003

Result Summary

Protocol ID:	S2WB1003
Clinical Study ID:	S2WB1003 (C95-035)
Official Title:	A study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan.
Phase:	Phase 1
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: Absence of significant pharmacodynamic or pharmacokinetic interaction with naratriptan and sumatriptan coadministration. Williams, PM MD, Kempsford, RD MD, Fuseau, E MD, Dow, J MD, and Smith, J MD 39th Annual Scientific Meeting of the American Association for the Study of Headache 6/22/1997 New York, New York Abstract: Absence of significant pharmacodynamic or pharmacokinetic interaction with naratriptan and sumatriptan co-administration. Williams, P, Kempsford, R, Fuseau, E, Dow, J, and Smith, J 8th Congress of the International Headache Society 6/10/1997 Amsterdam, Netherlands Abstract; no additional information beyond what is provided in the label. Williams P: Cephalalgia 1997;17(3):417.